ArticleBMC cancer2025
Automated machine learning-based unenhanced radiomics for identification of HER2-low breast cancers using diffusion-weighted imaging.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multiparametric MRI and artificial intelligence for non-invasive HER2 assessment in breast cancer: a comprehensive review.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RATIONALE AND
objectivesThe development of new antibody-drug conjugates necessitates precise identification of human epidermal growth factor receptor 2 (HER2)-low breast cancers. This study explores the potential application of an automated machine learning model to develop unenhanced apparent diffusion coefficient (ADC)-based radiomics for distinguishing between HER2-zero and HER2-low/ positive breast cancers, as well as HER2-zero and HER2-low breast cancers. MATERIALS AND
methodsThis study included 169 patients with invasive breast cancer (27 HER2-zero, 96 HER2-low and 46 HER2-positive). For each lesion, 1200 radiomics features and 11 clinicopathologic features were extracted. An automated machine learning pipeline was constructed using PyCaret for two binary classifications: HER2-zero versus HER2-low and HER2-zero versus HER2-low/ positive breast cancers. The performance of 13 machine learning models was assessed based on the training cohort and was compared using the area under the curve (AUC) to obtain the optimal model. This optimal model was subsequently validated using an internal validation cohort. Statistical analyses included Students’ t-tests, Mann-Whitney U tests or Chi-Square tests. The performance of the best model was evaluated using accuracy, AUC, sensitivity, positive predictive value and F1 score.
resultsIn distinguishing HER2-zero from HER2-low breast cancers, the Gradient Boosting Classifier exhibited superior classification performance with an AUC of 0.75 in the validation cohort. The Random Forest Classifier (RF) exhibited the best performance for the clinical-radiomics model, achieving an AUC of 0.79. For differentiating HER2-zero from HER2-low/ positive breast cancers, RF was optimal for both radiomics and radiomics-clinicopathologic models, each achieving an AUC of 0.82 in the validation cohort.
conclusionThe application of automated machine learning with ADC-based radiomics for the identification of HER2-low breast cancers is both feasible and advantageous.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.